Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PEG 3350 SODIUM SULFATE SODIUM CHLORIDE POTASSIUM CHLORIDE SODIUM ASCORBATE AND ASCORBIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PEG 3350 SODIUM SULFATE SODIUM CHLORIDE POTASSIUM CHLORIDE SODIUM ASCORBATE AND ASCORBIC ACID.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Osmotic laxative. Polyethylene glycol (PEG) 3350 and sodium sulfate act as osmotic agents that retain water in the colon, increasing stool water content and inducing diarrhea. Ascorbic acid and sodium ascorbate enhance colonic fluid retention and secretion through organic anion transporters.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Adults: 240 mL (or 2 sachets) reconstituted to 1 L water, administered orally or via nasogastric tube, in divided doses (e.g., 240 mL every 10-15 minutes) to a total volume of 1 L, followed by additional clear liquids as needed. For colonoscopy preparation, the typical regimen is a split-dose: first half (500 mL) in the evening before procedure, second half (500 mL) at least 3-5 hours before procedure.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
PEG 3350: Not applicable (minimal systemic absorption). Ascorbic acid: ~10-20 hours (dose-dependent, renal saturable reabsorption).
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily fecal (≥96%) as intact PEG 3350; absorbed fraction of electrolytes and ascorbate renally eliminated. Renal excretion of PEG <0.2%.
Category C
Category A/B
Electrolyte
Electrolyte